Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
STAT1 and IL-7 show diagnostic potential for ovarian carcinoma subtypes in cohort study
Two Tiny Signals Could Help Doctors Tell Apart Two Ovarian Cancers
A cohort study analyzed transcriptome data from 68 patients with high-grade and low-grade serous ovarian carcinoma.
Two tiny gene signals may help doctors distinguish between two ovarian cancer types when biopsy results are unclear, guiding the right treat…